Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Funding Is Secured At Visterra, Pearl

by Lisa M. Jarvis
November 19, 2012 | A version of this story appeared in Volume 90, Issue 47

Visterra has completed a $26 million Series A financing round. The Bill & Melinda Gates Foundation and Omega Funds joined three existing investors in the effort. Cambridge, Mass.-based Visterra will use the funds to develop its pipeline of antibodies to treat infectious diseases. Separately, Pearl Therapeutics has secured $65 million in its latest financing round, which involved existing investors. The Redwood City, Calif.-based firm will use the cash to initiate a Phase III study of PT003, a treatment for chronic obstructive pulmonary disease.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.